Table 3. VTE-related outcomes during... | American Society of Hematology

Table 3.

VTE-related outcomes during anticoagulation and after its discontinuation, by thrombophilia subgroups

	Patients not tested for IT		Tested patients (all)		Negative IT		All positive IT		Protein C deficiency		Protein S deficiency		AT deficiency		FVL		PT G20210A		Combined IT
	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y
During anticoagulation
Patients, N		82 729		21 089		12 667		8422		294		726		240		2248		1434		3480
Duration of therapy
Mean days (±SD)		264 ± 371		407 ± 594∗		362 ± 533∗		475 ± 670∗		520 ± 702∗		554 ± 712∗		507 ± 695∗		444 ± 644∗		477 ± 667∗		471 ± 672∗
Median days (IQR)		164 (97-282)		216 (133-398)∗		204 (125-373)∗		244 (146-467)∗		270 (154-545)∗		275 (151-609)∗		277 (129-572)∗		230 (133-434)∗		254 (159-472)∗		241 (148-462)∗
Outcomes
VTE recurrences	2016	3.46 (3.31-3.62)	581	2.58 (2.38-2.80)∗	310	2.57 (2.29-2.87)∗	271	2.59 (2.30-2.92)∗	8	1.95 (0.91-3.70)	25	2.38 (1.57-3.46)	16	5.31 (3.15-8.45)∗	70	2.69 (2.11-3.38)†	35	1.95 (1.38-2.68)∗	117	2.73 (2.27-3.26)‡
Recurrent DVT	1054	1.79 (1.68-1.90)	360	1.57 (1.42-1.74)†	191	1.56 (1.35-1.79)	169	1.59 (1.36-1.84)	6	1.45 (0.59-3.02)	17	1.60 (0.96-2.51)	11	3.45 (1.81-5.99)†	45	1.71 (1.26-2.26)	22	1.20 (0.77-1.79)	68	1.56 (1.22-1.96)
Recurrent PE	1006	1.70 (1.60-1.81)	235	1.02 (0.89-1.15)∗	126	1.02 (0.85-1.21)∗	109	1.01 (0.84-1.22)∗	2	0.48 (0.08-1.59)†	9	0.83 (0.40-1.52)†	5	1.58 (0.58-3.51)	25	0.93 (0.62-1.35)‡	14	0.76 (0.43-1.25)∗	54	1.23 (0.93-1.59)†
Major bleeding	2614	4.44 (4.27-4.61)	364	1.57 (1.41-1.73)∗	234	1.89 (1.66-2.14)∗	130	1.20 (1.00-1.42)∗	5	1.20 (0.44-2.67)∗	16	1.47 (0.87-2.34)∗	4	1.20 (0.38-2.90)‡	19	0.70 (0.43-1.07)∗	17	0.91 (0.55-1.43)∗	69	1.55 (1.22-1.95)∗
All-cause mortality	9692	16.2 (15.9-16.5)	449	1.91 (1.74-2.09)∗	248	1.97 (1.74-2.23)∗	201	1.84 (1.60-2.11)∗	6	1.43 (0.58-2.98)∗	14	1.27 (0.72-2.08)∗	12	3.60 (1.95-6.12)∗	28	1.03 (0.70-1.46)∗	15	0.80 (0.47-1.29)∗	126	2.81 (2.35-3.33)∗
Causes of death
PE	788	1.32 (1.23-1.41)	19	0.08 (0.05-0.12)∗	11	0.09 (0.05-0.15)∗	8	0.07 (0.03-0.14)∗	0	-	0	-	0	-	1	0.04 (0.00-0.18)∗	3	0.16 (0.04-0.44)∗	4	0.09 (0.03-0.22)∗
Bleeding	386	0.65 (0.58-0.71)	22	0.09 (0.06-0.14)∗	11	0.09 (0.05-0.15)∗	11	0.10 (0.05-0.17)∗	0	-	1	0.09 (0.00-0.45)‡	1	0.30 (0.02-1.48)	1	0.04 (0.00-0.18)∗	0	-	8	0.18 (0.08-0.34)∗
Cancer	3676	6.15 (5.96-6.36)	192	0.82 (0.71-0.94)∗	100	0.80 (0.65-0.96)∗	92	0.84 (0.68-1.03)∗	2	0.48 (0.08-1.58)∗	4	0.36 (0.12-0.88)∗	4	1.20 (0.38-2.89)∗	11	0.40 (0.21-0.70)∗	4	0.21 (0.07-0.52)∗	67	1.49 (1.17-1.89)∗
After anticoagulation discontinuation
Patients, n		26 049		10 048		6560		3488		92		266		68		958		632		1472
Duration of follow-up
Mean days (±SD)		423±623		688±891∗		673±869∗		717±930∗		790±1175∗		661±811∗		695±887†		722±897∗		773±996∗		696±928∗
Median days (IQR)		193 (64-516)		370 (127-903)∗		373 (130-891)∗		368 (123-938)∗		254 (88-984)		419 (130-927)∗		382 (111-997)†		393 (147-955)∗		430 (144-949)∗		331 (112-903)∗
Outcomes
VTE recurrences	2390	8.69 (8.35-9.05)	1172	6.99 (6.59-7.40)	711	6.58 (6.11-7.08)	461	7.72 (7.04-8.45)	18	11.8 (7.20-18.3)	27	6.12 (4.11-8.77)	9	7.86 (3.83-14.4)	135	8.09 (6.81-9.54)	92	8.06 (6.54-9.84)	180	7.34 (6.33-8.48)†
Recurrent DVT	1283	4.46 (4.22-4.71)	692	3.89 (3.61-4.19)‡	400	3.50 (3.17-3.85)∗	292	4.61 (4.10-5.16)	10	5.77 (2.93-10.3)	21	4.67 (2.97-7.02)	4	3.18 (1.01-7.68)	99	5.65 (4.62-6.85)†	57	4.62 (3.53-5.94)	101	3.88 (3.18-4.70)
Recurrent PE	1141	3.96 (3.73-4.19)	501	2.80 (2.56-3.05)∗	324	2.83 (2.54-3.15)∗	177	2.74 (2.36-3.16)∗	9	5.11 (2.49-9.37)	7	1.48 (0.65-2.93)‡	5	4.23 (1.55-9.36)	39	2.16 (1.56-2.92)∗	35	2.82 (1.99-3.87)†	82	3.09 (2.48-3.82)†
Major bleeding	342	1.14 (1.03-1.27)	98	0.52 (0.43-0.63)∗	60	0.50 (0.38-0.64)∗	38	0.56 (0.40-0.76)∗	1	0.50 (0.03-2.49)	2	0.42 (0.07-1.38)	0	-	6	0.32 (0.13-0.66)∗	7	0.53 (0.23-1.04)†	22	0.79 (0.51-1.18)
All-cause mortality	3949	13.1 (12.7-13.5)	460	2.43 (2.22-2.66)∗	288	2.38 (2.12-2.67)∗	172	2.51 (2.16-2.91)∗	1	0.50 (0.03-2.48)∗	19	3.95 (2.45-6.05)∗	6	4.64 (1.88-9.64)‡	25	1.32 (0.87-1.92)∗	24	1.80 (1.18-2.63)∗	97	3.46 (2.82-4.20)∗
Causes of death
PE	51	0.17 (0.13-0.22)	13	0.07 (0.04-0.11)‡	6	0.05 (0.02-0.10)‡	7	0.10 (0.04-0.20)	0	-	0	-	0	-	1	0.05 (0.00-0.26)	0	-	6	0.21 (0.09-0.45)
Bleeding	188	0.62 (0.54-0.72)	27	0.14 (0.10-0.20)∗	15	0.12 (0.07-0.20)∗	12	0.18 (0.09-0.30)∗	0	-	1	0.21 (0.01-1.02	0	-	2	0.11 (0.02-0.35)∗	2	0.15 (0.03-0.49)†	7	0.25 (0.11-0.49)‡
Cancer	1560	5.18 (4.92-5.44)	184	0.97 (0.84-1.12)∗	124	1.03 (0.86-1.22)∗	60	0.88 (0.67-1.12)∗	0	-	5	1.04 (0.38-2.30)∗	1	0.77 (0.04-3.81)†	12	0.63 (0.34-1.08)∗	5	0.37 (0.14-0.83)∗	37	1.32 (0.94-1.80)∗

	Patients not tested for IT		Tested patients (all)		Negative IT		All positive IT		Protein C deficiency		Protein S deficiency		AT deficiency		FVL		PT G20210A		Combined IT
	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y	N	Events per 100 patient-y
During anticoagulation
Patients, N		82 729		21 089		12 667		8422		294		726		240		2248		1434		3480
Duration of therapy
Mean days (±SD)		264 ± 371		407 ± 594∗		362 ± 533∗		475 ± 670∗		520 ± 702∗		554 ± 712∗		507 ± 695∗		444 ± 644∗		477 ± 667∗		471 ± 672∗
Median days (IQR)		164 (97-282)		216 (133-398)∗		204 (125-373)∗		244 (146-467)∗		270 (154-545)∗		275 (151-609)∗		277 (129-572)∗		230 (133-434)∗		254 (159-472)∗		241 (148-462)∗
Outcomes
VTE recurrences	2016	3.46 (3.31-3.62)	581	2.58 (2.38-2.80)∗	310	2.57 (2.29-2.87)∗	271	2.59 (2.30-2.92)∗	8	1.95 (0.91-3.70)	25	2.38 (1.57-3.46)	16	5.31 (3.15-8.45)∗	70	2.69 (2.11-3.38)†	35	1.95 (1.38-2.68)∗	117	2.73 (2.27-3.26)‡
Recurrent DVT	1054	1.79 (1.68-1.90)	360	1.57 (1.42-1.74)†	191	1.56 (1.35-1.79)	169	1.59 (1.36-1.84)	6	1.45 (0.59-3.02)	17	1.60 (0.96-2.51)	11	3.45 (1.81-5.99)†	45	1.71 (1.26-2.26)	22	1.20 (0.77-1.79)	68	1.56 (1.22-1.96)
Recurrent PE	1006	1.70 (1.60-1.81)	235	1.02 (0.89-1.15)∗	126	1.02 (0.85-1.21)∗	109	1.01 (0.84-1.22)∗	2	0.48 (0.08-1.59)†	9	0.83 (0.40-1.52)†	5	1.58 (0.58-3.51)	25	0.93 (0.62-1.35)‡	14	0.76 (0.43-1.25)∗	54	1.23 (0.93-1.59)†
Major bleeding	2614	4.44 (4.27-4.61)	364	1.57 (1.41-1.73)∗	234	1.89 (1.66-2.14)∗	130	1.20 (1.00-1.42)∗	5	1.20 (0.44-2.67)∗	16	1.47 (0.87-2.34)∗	4	1.20 (0.38-2.90)‡	19	0.70 (0.43-1.07)∗	17	0.91 (0.55-1.43)∗	69	1.55 (1.22-1.95)∗
All-cause mortality	9692	16.2 (15.9-16.5)	449	1.91 (1.74-2.09)∗	248	1.97 (1.74-2.23)∗	201	1.84 (1.60-2.11)∗	6	1.43 (0.58-2.98)∗	14	1.27 (0.72-2.08)∗	12	3.60 (1.95-6.12)∗	28	1.03 (0.70-1.46)∗	15	0.80 (0.47-1.29)∗	126	2.81 (2.35-3.33)∗
Causes of death
PE	788	1.32 (1.23-1.41)	19	0.08 (0.05-0.12)∗	11	0.09 (0.05-0.15)∗	8	0.07 (0.03-0.14)∗	0	-	0	-	0	-	1	0.04 (0.00-0.18)∗	3	0.16 (0.04-0.44)∗	4	0.09 (0.03-0.22)∗
Bleeding	386	0.65 (0.58-0.71)	22	0.09 (0.06-0.14)∗	11	0.09 (0.05-0.15)∗	11	0.10 (0.05-0.17)∗	0	-	1	0.09 (0.00-0.45)‡	1	0.30 (0.02-1.48)	1	0.04 (0.00-0.18)∗	0	-	8	0.18 (0.08-0.34)∗
Cancer	3676	6.15 (5.96-6.36)	192	0.82 (0.71-0.94)∗	100	0.80 (0.65-0.96)∗	92	0.84 (0.68-1.03)∗	2	0.48 (0.08-1.58)∗	4	0.36 (0.12-0.88)∗	4	1.20 (0.38-2.89)∗	11	0.40 (0.21-0.70)∗	4	0.21 (0.07-0.52)∗	67	1.49 (1.17-1.89)∗
After anticoagulation discontinuation
Patients, n		26 049		10 048		6560		3488		92		266		68		958		632		1472
Duration of follow-up
Mean days (±SD)		423±623		688±891∗		673±869∗		717±930∗		790±1175∗		661±811∗		695±887†		722±897∗		773±996∗		696±928∗
Median days (IQR)		193 (64-516)		370 (127-903)∗		373 (130-891)∗		368 (123-938)∗		254 (88-984)		419 (130-927)∗		382 (111-997)†		393 (147-955)∗		430 (144-949)∗		331 (112-903)∗
Outcomes
VTE recurrences	2390	8.69 (8.35-9.05)	1172	6.99 (6.59-7.40)	711	6.58 (6.11-7.08)	461	7.72 (7.04-8.45)	18	11.8 (7.20-18.3)	27	6.12 (4.11-8.77)	9	7.86 (3.83-14.4)	135	8.09 (6.81-9.54)	92	8.06 (6.54-9.84)	180	7.34 (6.33-8.48)†
Recurrent DVT	1283	4.46 (4.22-4.71)	692	3.89 (3.61-4.19)‡	400	3.50 (3.17-3.85)∗	292	4.61 (4.10-5.16)	10	5.77 (2.93-10.3)	21	4.67 (2.97-7.02)	4	3.18 (1.01-7.68)	99	5.65 (4.62-6.85)†	57	4.62 (3.53-5.94)	101	3.88 (3.18-4.70)
Recurrent PE	1141	3.96 (3.73-4.19)	501	2.80 (2.56-3.05)∗	324	2.83 (2.54-3.15)∗	177	2.74 (2.36-3.16)∗	9	5.11 (2.49-9.37)	7	1.48 (0.65-2.93)‡	5	4.23 (1.55-9.36)	39	2.16 (1.56-2.92)∗	35	2.82 (1.99-3.87)†	82	3.09 (2.48-3.82)†
Major bleeding	342	1.14 (1.03-1.27)	98	0.52 (0.43-0.63)∗	60	0.50 (0.38-0.64)∗	38	0.56 (0.40-0.76)∗	1	0.50 (0.03-2.49)	2	0.42 (0.07-1.38)	0	-	6	0.32 (0.13-0.66)∗	7	0.53 (0.23-1.04)†	22	0.79 (0.51-1.18)
All-cause mortality	3949	13.1 (12.7-13.5)	460	2.43 (2.22-2.66)∗	288	2.38 (2.12-2.67)∗	172	2.51 (2.16-2.91)∗	1	0.50 (0.03-2.48)∗	19	3.95 (2.45-6.05)∗	6	4.64 (1.88-9.64)‡	25	1.32 (0.87-1.92)∗	24	1.80 (1.18-2.63)∗	97	3.46 (2.82-4.20)∗
Causes of death
PE	51	0.17 (0.13-0.22)	13	0.07 (0.04-0.11)‡	6	0.05 (0.02-0.10)‡	7	0.10 (0.04-0.20)	0	-	0	-	0	-	1	0.05 (0.00-0.26)	0	-	6	0.21 (0.09-0.45)
Bleeding	188	0.62 (0.54-0.72)	27	0.14 (0.10-0.20)∗	15	0.12 (0.07-0.20)∗	12	0.18 (0.09-0.30)∗	0	-	1	0.21 (0.01-1.02	0	-	2	0.11 (0.02-0.35)∗	2	0.15 (0.03-0.49)†	7	0.25 (0.11-0.49)‡
Cancer	1560	5.18 (4.92-5.44)	184	0.97 (0.84-1.12)∗	124	1.03 (0.86-1.22)∗	60	0.88 (0.67-1.12)∗	0	-	5	1.04 (0.38-2.30)∗	1	0.77 (0.04-3.81)†	12	0.63 (0.34-1.08)∗	5	0.37 (0.14-0.83)∗	37	1.32 (0.94-1.80)∗

Patients not tested for IT were used as reference for all comparisons with the remaining subgroups.

AT, antithrombin; DVT, deep venous thrombosis; IQR, interquartile range; SD, standard deviation.

P < .001.

P < .05.

P < .01.

This Feature Is Available To Subscribers Only